Traws Pharma Extends CMC Services Contract With ChemDiv for Ratutrelvir Clinical Development
Traws Pharma Inc. has extended its contract with ChemDiv for CMC services to support the clinical development of ratutrelvir, an oral antiviral for COVID-19 in Phase 2 trials. The agreement includes CMC process research, medicinal chemistry support, and clinical pharmacology consulting. Additionally, Expert Systems has also extended its contract with Traws Pharma for predictive safety pharmacology services using AI to aid further clinical development of ratutrelvir.
Traws Pharma Inc. has extended its collaboration with ChemDiv for Chemistry, Manufacturing and Controls (CMC) services to support the clinical development of ratutrelvir, an oral antiviral treatment for COVID-19 currently in Phase 2 clinical trials. The updated agreement includes CMC process research and scale-up for manufacturing, medicinal chemistry support, translational pharmacology services, and clinical pharmacology consulting. Additionally, Expert Systems has extended its contract with Traws Pharma to provide predictive safety pharmacology services using its AI-enabled platform to support further clinical development of ratutrelvir. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA11152) on October 30, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
